In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
from Top Health News -- ScienceDaily https://ift.tt/2Q7y3t5
Subscribe to:
Post Comments (Atom)
-
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response with just one ...
-
Three treaties between the US and Hong Kong were suspended, the latest move to pressure China. from Yahoo News - Latest News & Headl...
-
Researchers observed a rise in adult central nervous system (CNS) infections, primarily aseptic meningitis caused by the varicella zoster vi...
No comments:
Post a Comment